Effect of zoledronic acid dosing every 3 months in patients with prostate cancer with skeletal metastases: A multicenter prospective exploratory study with matched historical controls

Int J Urol. 2018 Aug;25(8):758-759. doi: 10.1111/iju.13703. Epub 2018 May 14.

Authors

Akihiro Yano¹, Yoshiaki Arai², Sachi Kitayama³, Yukihiro Otsuka⁴, Suguru Shirotake⁵, Satoru Kawakami¹

Affiliations

¹ Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
² Department of Urology, Nishi-Omiya Hospital, Saitama, Japan.
³ Department of Urology, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan.
⁴ Department of Urology, Omori Red Cross Hospital, Tokyo, Japan.
⁵ Department of Urologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.

PMID: 29761556
DOI: 10.1111/iju.13703

No abstract available

Publication types

Multicenter Study

MeSH terms

Aged
Aged, 80 and over
Bone Density Conservation Agents / administration & dosage*
Bone Neoplasms / drug therapy*
Bone Neoplasms / secondary
Fractures, Spontaneous / prevention & control
Humans
Male
Middle Aged
Multivariate Analysis
Propensity Score
Prospective Studies
Prostate-Specific Antigen / blood
Prostatic Neoplasms / mortality*
Prostatic Neoplasms / pathology
Survival Analysis
Zoledronic Acid / administration & dosage*

Substances

Bone Density Conservation Agents
Zoledronic Acid
Prostate-Specific Antigen